MC4R was mainly used to treat increased food intake and obesity caused by the deletion of POMC gene or LEPR gene, and it could reduce hunger and cause weight loss, and 80% of the POMC gene deletion patients and 45% of the LEPR gene deletion patients had a weight loss of at least 10%, indicating that the MC4R agonist can effectively alleviate the abnormal melanocortin pathway activation caused by the POMC gene or LEPR gene deletion in clinical practice. Here, POMC is linked to obesity due to melanocortin 4 receptor deficiency.